Literature DB >> 31713811

Trifarotene: First Approval.

Lesley J Scott1.   

Abstract

Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31713811     DOI： 10.1007/s40265-019-01218-6

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.

Authors:  Etienne Thoreau; Jean-Marie Arlabosse; Claire Bouix-Peter; Sandrine Chambon; Laurent Chantalat; Sébastien Daver; Laurence Dumais; Gwenaëlle Duvert; Angélique Feret; Gilles Ouvry; Jonathan Pascau; Catherine Raffin; Nicolas Rodeville; Catherine Soulet; Samuel Tabet; Sandrine Talano; Thibaud Portal
Journal:  Bioorg Med Chem Lett       Date:  2018-04-15       Impact factor: 2.823

2.  Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.

Authors:  Jerry Tan; Diane Thiboutot; Georg Popp; Melinda Gooderham; Charles Lynde; James Del Rosso; Jonathan Weiss; Ulrike Blume-Peytavi; Jolanta Weglovska; Sandra Johnson; Lawrence Parish; Dagmara Witkowska; Nestor Sanchez Colon; Alessandra Alió Saenz; Faiz Ahmad; Michael Graeber; Linda Stein Gold
Journal:  J Am Acad Dermatol       Date:  2019-02-22       Impact factor: 11.527

3.  Topical Retinoids in Acne Vulgaris: A Systematic Review.

Authors:  Sree S Kolli; Danielle Pecone; Adrian Pona; Abigail Cline; Steven R Feldman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

4.  Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments

Authors:  Anna Chien
Journal:  J Drugs Dermatol       Date:  2018-12-01       Impact factor: 2.114

5.  Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene.

Authors:  J Aubert; D Piwnica; B Bertino; S Blanchet-Réthoré; I Carlavan; S Déret; B Dreno; B Gamboa; A Jomard; A P Luzy; P Mauvais; C Mounier; J Pascau; I Pelisson; T Portal; M Rivier; P Rossio; E Thoreau; E Vial; J J Voegel
Journal:  Br J Dermatol       Date:  2018-07-04       Impact factor: 9.302

Review 6.  Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment.

Authors:  Anders Vahlquist; Judith Fischer; Hans Törmä
Journal:  Am J Clin Dermatol       Date:  2018-02       Impact factor: 7.403

7.  Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.

Authors:  U Blume-Peytavi; J Fowler; L Kemény; Z Draelos; F Cook-Bolden; T Dirschka; L Eichenfield; M Graeber; F Ahmad; A Alió Saenz; P Rich; E Tanghetti
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-08-20       Impact factor: 6.166
  7 in total
  3 in total

Review 1.  Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations.

Authors:  Daniela Milosheska; Robert Roškar
Journal:  Adv Ther       Date:  2022-10-11       Impact factor: 4.070

Review 2.  Vitamin A, systemic T-cells, and the eye: Focus on degenerative retinal disease.

Authors:  Arun J Thirunavukarasu; A Catharine Ross; Rose M Gilbert
Journal:  Front Nutr       Date:  2022-07-18

3.  Clinical study on acupuncture treatment of gastrointestinal damp-heat acne.

Authors:  Ping-Ping Duan; Chao-Qun Yan; Hui-Shang Feng; Yuan Chen; Ning Sun; Ya-Qi Yao; Kai-Bing Tian; Guang-An Wang
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.